
Hikma Remains Constituent of FTSE4Good Index Series

London, 10 September 2018 - Hikma Pharmaceuticals PLC (Hikma Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) - the multinational generic pharmaceutical company - continues to be recognized as a constituent of the FTSE4Good Index Series for positive environmental, social and governance practices.

"We are pleased to remain members of the FTSE4Good Sustainability Index in recognition of our commitment to globally recognised corporate responsibility standards. Since our founding 40 years ago, we have been committed to conducting our business in a responsible manner that brings about positive change in our local and global communities. We will continue to be active partners in shaping a sustainable future by engaging with our stakeholders, minimizing our environmental impact and improving transparency," commented Hana Darwazeh Ramadan, Vice President of Corporate Communications and Corporate Responsibility at Hikma Pharmaceuticals. "We have prioritized our activities around five Sustainable Development Goals (SDGs) that most closely align with our business and social engagement strategy: Good Health and Wellbeing, Quality Education, Gender Equality, Decent Work and Economic Growth, Industry, as well as Innovation and Infrastructure," she added.

Since 2007, Hikma has been an active member of the UN Global Compact (UNGC), the world's largest corporate sustainability initiative mobilizing companies to do business responsibly by aligning their strategies and operations with principles on human rights, labour, environment and anti-corruption; and to take strategic actions to advance broader societal goals, such as the UN Sustainable Development Goals, with an emphasis on collaboration and innovation.

-Ends-

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

Hana Darwazeh Ramadan
Email: Media@Hikma.com
Tel: +962 6 580 2900

This press release has been distributed by Bidaya Corporate Communications on behalf of Hikma Pharmaceuticals.

For more information or assistance, please contact us at:



BIDAYA
CORPORATE COMMUNICATIONS

Tel: +962 6 585 4002/6

Fax: +962 6 585 3001

P.O. Box: 930391, Amman 11193, Jordan

Email: media@bidayacorp.com